Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,413 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
66/100
We examined the impact of physical activity (PA) on longitudinal change in hippocampal volume in cognitively intact older adults at varying genetic risk for the sporadic form of Alzheimer's disease (AD).
-
66/100
Researchers conducted a large, two-stage meta-analysis of genome-wide association studies in individuals of European ancestry.
Why it matters
A meta-analysis of 74,046 individuals reporting 11 new susceptibility loci for Alzheimer's disease. Risk loci point to biology worth investigating; they do not by themselves give a treatment or a way to prevent the disease.
-
Huperzine A is a Chinese herb extract used for Alzheimer's disease.
Why it matters
This meta-analysis of 20 randomized trials examined the benefits and harms of Huperzine A, a Chinese herb extract, for treating Alzheimer's disease. It reviews existing trial evidence on a treatment but does not establish a cure or prevention.
-
Previous studies of Aβ plasma as a biomarker for Alzheimer's disease (AD) obtained conflicting results.
Why it matters
Plasma Aβ measurements had limited value for classifying who had Alzheimer's disease and only modest value for predicting progression over 3 years. The authors suggest that longer follow-up with repeated plasma Aβ measurements might be needed before these tests could be useful.
-
The authors sought to identify new susceptibility loci for Alzheimer's disease through a staged association study and by testing suggestive loci reported by the Alzheimer's Disease Genetic Consortium in a companion paper.
Why it matters
Reports common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP associated with Alzheimer's disease. These associations nominate genes for further work and are not treatments.
-
Comprehensive and unbiased meta-analysis of all published and unpublished data from case-control studies for the SORL1 single-nucleotide polymorphisms (SNPs) that had been repeatedly assessed across studies.
Why it matters
This meta-analysis reexamined the association between SORL1 variants and Alzheimer's disease across many case-control datasets. It addresses genetic risk association only and does not show that targeting SORL1 treats, cures, or prevents the disease.
-
The findings support the clinical efficacy of CR in early-stage AD.
Why it matters
In this single-blind randomized controlled trial, cognitive rehabilitation significantly improved ratings of goal performance and satisfaction in people with early-stage Alzheimer's disease, while the other two groups did not change. This is a nonpharmacological approach to helping with individually relevant goals, not a treatment that changes the disease course.
-
NPTs emerge as a useful, versatile and potentially cost-effective approach to improve outcomes and QoL in ADRD for both the PWD and CG.
Why it matters
Reviewing 179 randomized trials of non-drug therapies, the strongest evidence (Grade A) was for multicomponent caregiver interventions delaying placement in a care facility. This is about managing care and quality of life, not curing or preventing the underlying disease.
-
Follow-up case-control association study.
Why it matters
This follow-up case-control study replicated associations between variants in the CLU, CR1, and PICALM genes and late-onset Alzheimer's disease. It is genetic association research and does not test any treatment, cure, or prevention.
-
Among the 158 participants who accurately recalled their Alzheimer disease risk assessment 6 weeks after risk disclosure, 75 (47.5%) believed their Alzheimer disease risk was more than 5% points different from the Alzheimer disease risk estimate they were given.
Why it matters
Among 158 people who accurately recalled their genetics-based Alzheimer's disease risk estimate, 47.5% believed their risk was more than 5 percentage points different from what they were told, mostly higher. This is about how people perceive risk information and does not test any treatment, cure, or prevention.
-
Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia.
Why it matters
In this small trial of 28 adults with glucose intolerance, six months of aerobic exercise improved executive function, fitness, and insulin sensitivity. The study was small and did not test whether exercise prevents or treats Alzheimer's disease.
-
This study undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease involving over 16,000 individuals.
Why it matters
A genome-wide association study reporting variants at CLU and PICALM associated with Alzheimer's disease. An association marks genes worth studying further; it does not show that acting on them treats or prevents the disease.
-
In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens.
Why it matters
In a 24-week randomized trial of 433 people with mild to moderate Alzheimer's (MMSE 10–22) who were already on a stable cholinesterase inhibitor (donepezil, rivastigmine or galantamine), adding memantine 20 mg once daily showed "no statistically significant differences" from placebo on thinking (ADAS-cog), clinician-rated change (CIBIC-Plus), daily activities, behaviour or MMSE. Side-effect rates were similar in both groups. The result applies to this add-on setting and time frame. It does not test memantine alone or in more advanced disease.
-
The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD).
Why it matters
This randomised controlled trial found that one year of treatment with the anti-inflammatory drug indomethacin did not slow cognitive decline in people with mild to moderate Alzheimer's disease. It reports a null result for this treatment.
-
66/100
Alzheimer disease (AD) has a significant impact on caregivers.
Why it matters
In this substudy of the IDEAL trial, more than 70% of 1059 caregivers preferred rivastigmine patches over capsules for ease of use and satisfaction. It addresses caregiver preference for a delivery method and does not show that the drug treats, cures, or prevents Alzheimer's disease.
-
Pittsburgh Compound B PET findings match histopathologic reports of beta-amyloid (Abeta) distribution in aging and dementia.
Why it matters
Using PET imaging, this study found that amyloid burden was elevated in every person with Alzheimer's disease, lower and more variable in dementia with Lewy bodies, absent in frontotemporal dementia, and present in some people with mild cognitive impairment and even some healthy controls. It shows that amyloid imaging can reveal brain changes, but it does not provide a treatment, cure or prevention.
-
Patients treated with LY451395 did not show a statistically significant separation from patients taking placebo on the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the primary outcome measure.
Why it matters
In 181 patients with mild to moderate Alzheimer's disease, LY451395 did not show a statistically significant separation from placebo on the primary cognitive outcome, with only a marginal change on the Neuropsychiatric Inventory. This drug did not demonstrate a cognitive benefit.
-
Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression.
Why it matters
This case-control study found that certain plasma proteins, including complement factor H and alpha-2-macroglobulin, were elevated in people with Alzheimer's disease and correlated with disease severity. These findings suggest blood may be a source of biomarkers, but they do not provide a treatment, cure, or prevention.
-
66/100
Diabetes mellitus did not increase the risk of incident AD in the Framingham cohort overall; however, DM may be a risk factor for AD in the absence of other known major AD risk factors.
-
Longitudinal studies will be required to determine the association of elevated [(11)C]PIB binding and risk of developing dementia of the Alzheimer type.
Why it matters
In 41 people without dementia (aged 20 to 86) and 10 people with Alzheimer-type dementia, each given one PET scan with the amyloid tracer PIB, the authors report that elevated tracer binding in nondemented people "suggests that [(11)C]PIB amyloid imaging may be sensitive for detection of a preclinical Alzheimer disease state." Because each person was scanned once, the study could not show whether that binding leads to dementia; the authors write that "longitudinal studies will be required" to test that. It is an imaging study and does not test any treatment or prevention.
-
Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial.
Why it matters
In this small pilot trial, atorvastatin reduced circulating cholesterol levels and produced a positive signal on each clinical outcome measure compared with placebo, reaching significance for one measure. Because it was a preliminary proof-of-concept study, the results are not definitive.
-
This cost-consequence analysis reveals economic benefits of treatment of moderate to severe AD with donepezil.
Why it matters
In 290 patients with moderate to severe Alzheimer's disease, donepezil was associated with a net societal cost saving of Can 332 dollars over 24 weeks compared with placebo. This is an economic evaluation of costs, not evidence about treating, curing, or preventing Alzheimer's disease.
-
Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization.
Why it matters
In this 6-week trial of 206 nursing home residents with Alzheimer disease and psychotic or behavioral symptoms, low-dose olanzapine (5 and 10 mg/d) produced significant improvement in agitation/aggression and psychosis compared with placebo. Low-dose olanzapine was significantly superior to placebo and well tolerated in this population.
-
This multicentre, open-label study evaluated the long-term efficacy and safety of donepezil in the treatment of patients with mild to moderately severe Alzheimer's disease (AD).
Why it matters
This open-label study followed 133 patients with mild to moderately severe Alzheimer's disease who took donepezil for up to 240 weeks to assess long-term efficacy and safety. It reports on an existing drug's long-term use, not on curing or preventing the disease.
-
66/100
Our data from a population-based study support the hypothesis that estrogen-replacement therapy is associated with a reduced prevalence of Alzheimer's disease in postmenopausal women.
Why it matters
In this survey of postmenopausal women in Italy, estrogen use was less frequent among Alzheimer's disease patients than among nonpatients, and the inverse association remained significant after adjustment for several factors. This is an observed association in a population survey, not evidence that estrogen-replacement therapy prevents or treats Alzheimer's disease.
From across this topic
10 of the 5,374 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- A Novel Mouse Model for Investigating ARIAs in Response to Anti-Abeta Immunotherapy
- Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
- The role of microbial amyloid in neurodegeneration
- Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease
- Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials
- Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies
- Plasma proteomics for the identification of Alzheimer disease
- Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
- Reduced retinal thickness and risk of Alzheimer’s disease: a bidirectional two-sample Mendelian randomization study